Continuous Infusion Vs Intermittent Bolus Mesna with Post-Transplant Cyclophosphamide Following Hematopoietic Stem Cell Transplantation

Post-transplant cyclophosphamide (PTCy) is an effective strategy used in the prevention of graft-vs-host-disease (GVHD) during hematopoietic stem cell transplantation (HCT). Hemorrhagic cystitis (HC) is a major complication associated with high-dose cyclophosphamide in 10-40% of patients [Urology; 100:16-19]. Sodium 2-mercaptoethanesulfonate (MESNA) binds and inactivates acrolein in the urinary tract, preventing tissue injury. While international guidelines endorse MESNA, there is no consensus regarding the optimal method of administration with high-dose cyclophosphamide (J Clin Oncol.2002;20:2895 –2903).

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Lindsay Orton, Katie S. Gatwood, Eden Biltibo, Andrew Jallouk, James H. Jerkins, Reena V Jayani, Dr. Bhagirathbhai Dholaria, Tae K Kon Kim, Bipin N. Savani, Leena Choi, Elizabeth McNeer, Adetola A. Kassim Tags: 149 Source Type: research